Cushman & Wakefield Grows its Capital Advisory business in Greater China and Australia

2 years ago

HONG KONG SAR - Media OutReach - 28 June 2023 - Cushman & Wakefield is pleased to announce new senior…

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

2 years ago

Expansion of AZ Forest programme raises commitment to plant 200 million trees across six continents by 2030 New reforestation projects…

Nidec Files a Civil Action and a Complaint against Toyo Keizai Inc. and Former Employee, etc.

2 years ago

KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO: 6594) (OTC US: NJDCY) (“Nidec” or the “Company”) announced today that it has instituted an…

Black & Veatch Appoints Industry Veteran as President, Asia-Pacific and India as Company Continues Growth Across the Regions

2 years ago

Narsingh Chaudhary to succeed Hoe Wai Cheong who will retire at the end of 2023 BANGKOK--(BUSINESS WIRE)--Black & Veatch, a…

BBH Greater China ETF Investor Survey: Greater China ETF Market Grows as Product Platform Expands and Investors Evolve Usage

2 years ago

The number of investors with more than 25% of their portfolio invested in ETFs is up 11% from 2022 Hong…

The University of Hong Kong hosts APRU Presidents’ Meeting on Sustainable Future Solutions

2 years ago

HONG KONG SAR - Media OutReach - 28 June 2023 - The University of Hong Kong (HKU) welcomed academic leaders…

Navigator and Fullerton Fund Management Launch Collaboration to Expand Range of Investment Solutions

2 years ago

SINGAPORE - Media OutReach - 28 June 2023 - Navigator Investment Services Ltd ("Navigator"), an integrated investment company by Singlife,…

KLab Inc.’s Subsidiary BLOCKSMITH&Co. Announces Development of BLQS Verse and Adoption of user-contributed short vertical video quiz application “QAQA” on Oasys

2 years ago

TOKYO, JAPAN - Media OutReach - 28 June 2023 - KLab Inc. (Head office: Minato-ku, Tokyo, President & CEO: Hidekatsu…

Microba Commences Phase I Clinical Trial for IBD Therapeutic

2 years ago

First participants have been successfully dosed in a Phase I Clinical Trial of MAP 315, Microba’s lead Therapeutic Program in…